InvestorsHub Logo
Post# of 253535
Next 10
Followers 839
Posts 120671
Boards Moderated 13
Alias Born 09/05/2002

Re: DewDiligence post# 81705

Sunday, 11/01/2009 2:52:37 PM

Sunday, November 01, 2009 2:52:37 PM

Post# of 253535
Sanofi Reports 3Q09 Annualized Lovenox Sales of $4.4B

[Sanofi’s reporting currency is the Euro, but the growth rates reported below are in local currencies unless otherwise specified. Tallying growth in local currencies is a way to track the change in volume and price irrespective of exchange rates. The figures below are annualized, i.e. they are 4x the reported 3Q09 numbers.]


Worldwide Lovenox sales rose 14% year-over-year (18% in Euros) to an annualized rate of €3.0B, which is $4.4B at the current exchange rate.

In the US (where MNTA and NVS have filed an application to sell generic Lovenox), annualized 3Q09 Lovenox sales rose 8% in dollars to $2.6B.

The breakdown of 3Q09 sales by geography is as follows (growth rates are year-over-year in local currencies):

US: €1.77B (59% of total), 8% growth
EU: €880M (29% of total), 23% growth
RoW: €330M (11% of total), 19% growth
===
Total: €2.99B, 14% growth

Source: http://en.sanofi-aventis.com/binaries/20091030_results_q3_2009_en_tcm28-26643.pdf


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.